



Western
UNIVERSITY • CANADA

Parkinson's Disease

Penny A. MacDonald, MD, PhD FRCP(C)

Canada Research Chair

Cognitive Neuroscience and Neuroimaging


Clinical Neurological Sciences

Overview


- review the epidemiology
- pathophysiology of motor symptoms
- motor symptoms
- non-motor symptoms
- effect of dopaminergic therapy
- effect of DBS
- research

PD: Definition & Epidemiology


- progressive multi-symptom illness
- premature, focal neurodegeneration
- cardinal, motor symptoms 2° loss of dopamine-producing cells in SN that supply the (dorsal) striatum
- prevalence 1-2% over age 60 in industrialized countries
- 85% of parkinsonism presentations
- M:F ~ 1.5:1
- Average age of onset ~ 60 years of age (wide range)
- disease duration is complicated, influenced by a number of factors such as age of onset and presence of dementia



Poirier, L.J. and Sourkes, T.L., 1965. Influence of the substantia nigra on the catecholamine content of the striatum. *Brain* **88**, pp. 181–192.



Poirier, L.J. and Sourkes, T.L., 1965. Influence of the substantia nigra on the catecholamine content of the striatum. *Brain* **88**, pp. 181–192.



Poirier, L.J. and Sourkes, T.L., 1965. Influence of the substantia nigra on the catecholamine content of the striatum. *Brain* **88**, pp. 181–192.

Before diagnosis -

Stages 1 & 2 :

- ▣ loss of smell
- ▣ disturbance of sleep and wakefulness
- ▣ lowered blood pressure
- ▣ constipation
- ▣ anxiety/depression


At diagnosis -

Stages 3 & 4:

- ▣ movement problems
- ▣ subtle thinking problems

Later disease - Stages 5 & 6:

- ▣ worsening movement problems
- ▣ more significant thinking problems/dementia
- ▣ worsening anxiety/depression
- ▣ hallucinations/paranoia/delusions (i.e., false beliefs)



PD: Definition & Epidemiology

- progressive multi-system illness
- premature, focal neurodegeneration
- cardinal, motor symptoms 2° loss of dopamine-producing cells in SN that supply the (dorsal) striatum
- prevalence 1-2% over age 60 in industrialized countries
- 85% of extrapyramidal movement disorder presentations
- M:F ~ 1.5:1
- Average age of onset ~ 60 years of age (wide range)
- disease duration is complicated, influenced by a number of factors such as age of onset and presence of dementia

Familial Parkinsonism

AD

- Fahr's
- Early onset Parkinsonism
 - a-synuclein - PARK1/4 (1997); < 0.05%
 - LRRK2 - PARK8 (2004); 5-10%
- Juvenile Huntington's
- SCA2
- SCA3 (Machado-Joseph)

AR

- Early onset Parkinsonism
 - Parkin - PARK2 10-20%
 - DJ-1 - PARK7 1-2%
 - PINK1 - PARK6 2-7%
- Gaucher's Disease
- Wilson's Disease
- Parkinsonism-Dementia Complex of Guam+ ALS
- Guadeloupean Parkinsonism
- Lubag -dystonia(DYT 3)
- PKAN • Neuroaxonal dystrophy

Sporadic Parkinsonism

- Idiopathic Parkinson's Disease
- Parkinson's Plus Syndromes
 - PSP, CBD, MSA, DLB
- vascular
- Toxicity [MN; CO; methanol neuroleptics/tetrabenazine; MPTP; Parkinsonism-Dementia Complex of Guam+ ALS (cycad nut)]
- Post-encephalitic Parkinsonism (not since 1960)
- FTD with Parkinsonism –17
- Fahr's (bg ca^{2+} idiopathic; hypoparathyroidism, 2° hyperparathyroidism)
- Guadeloupean Parkinsonism (annoma muricata)
- recurrent trauma

Parkinson's Disease (PD): Definition & Epidemiology

- progressive multi-system illness
- premature, focal neurodegeneration
- cardinal, motor symptoms 2° loss of dopamine-producing cells in SN that supply the (dorsal) striatum
- prevalence 1-2% over age 60 in industrialized countries
- 85% of parkinsonism presentations
- M:F ~ 1.5:1
- Average age of onset ~ 60 years of age (wide range)
- disease duration is complicated, influenced by a number of factors such as age of onset and presence of dementia



Motor symptoms

- rest tremor
 - maximal at rest, decreases or disappears when muscles are contracted/with actions
 - especially affects the thumb and index finger
 - ‘pill-rolling’ appearance, 4-6Hz
 - can appear in hands, legs, head, jaw, **chin**, voice/stuttering
- Rigidity (cogwheeling if patient has tremor)
 - limb, axial, stooped posture (camptocormia, pisa syndrome)


Aside: Essential Tremor

- essential tremor
 - postural + kinetic tremor
 - overflow tremor can make tremor seem to occur at rest
 - be sure patient is relaxed and muscles not contracted
 - should not affect legs
 - often slight tremor present many years (even decades) before assessment




Motor symptoms

- rest tremor
 - maximal at rest, decreases or disappears when muscles are contracted/with actions
 - especially affects the thumb and index finger
 - ‘pill-rolling’ appearance, 4-6Hz
 - can appear in hands, legs, head, jaw, **chin**, voice/stuttering
- Rigidity (cogwheeling if patient has tremor)
 - limb; axial (stooped posture, camptocormia, anterocollis, pisa syndrome)



Camptocormia, Anterocollis, and Pisa Syndrome





Motor symptoms

- bradykinesia
 - slowed gait, position changes, hand/finger movements
 - postural instability–slowed righting
- hypokinesia/akinesia
 - masked facies, decreased blinking
 - drooling 2° decreased swallowing
 - decreased spontaneous movements
 - micrographia; hypophonia; dysarthria
- dysphagia
- dystonia (generalized, limb, task-specific)
- postural instability (late)



Non-motor symptoms

- anosmia
- autonomic dysfunction
 - constipation/nausea/early satiety
 - hypotension & orthostatic hypotension
 - sexual dysfunction
 - frequency/nocturia
 - runny nose; drooling
 - altered patterns of perspiration/flushing



Non-motor symptoms

- anxiety/depression (serotonin; noradrenaline)
- apathy/lack of interest or motivation
- cognitive impairment (subtle early; dementia late)
- psychosis (hallucinations, delusions, paranoia; late)



Non-motor symptoms

- disturbance of wakefulness
 - somnolence; increased daytime sleeping (noradrenaline, serotonin, histamine, orexin)
- disturbance of sleep
 - restless leg syndrome
 - increased dreaming/vivid dreams
 - REM sleep behaviour disorder
 - insomnia, difficulty maintaining sleep (acetylcholine, GABA, histamine, orexin)



Non-motor symptoms

- vision changes
 - impaired colour discrimination
 - glaucoma (need periodic ophtho
- skin problems
 - excessively oily skin
 - seborrheic dermatitis
 - increased risk of melanoma (educate patients about vigilance)
- pain

PD Diagnosis

At least THREE of the following supportive (prospective) criteria:

- unilateral onset
- persistent asymmetry primarily affecting side of onset
- progressive disorder
- excellent response (70–100%) to levodopa
- severe levodopa induced chorea (dyskinesia)**
- levodopa response for 5 years or more
- clinical course of 10 years or more

PD Plus Syndromes

Tauopathies (4-repeat tau)

- Progressive Supranuclear Palsy (PSP)
- Corticobasal Ganglionic Degeneration (CBGD)

α -synucleinopathies

- Multiple-System's Atrophy (MSA)
- Lewy Body Dementia (DLB)*

(remember IPD is α -synucleinopathy)

* often also AD pathology

Red Flags: Consider 'PD Plus Syndrome' or Genetic Form

- early/prominent dementia
- early falls/postural instability
- early hallucinations
- eye-movement abnormalities
- symmetrical signs
- early or significant bulbar dysfunction
- early gait disorder
- wheelchair dependence within 5 years
- early autonomic failure
- sleep apnea/gasping respirations
- apraxia
- alien limb
- no response to L-dopa
- * numerous 1st degree relatives with PD
- * onset before age 40

PD & PD Plus: Presentation

- Motor > Cognitive
 - PD
 - MSA
 - CBD
- Cognitive > Motor
 - PSP
 - DLB
 - CBD
- Asymmetric
 - PD
 - CBD
 - DLB
- Symmetric
 - PSP
 - MSA
 - DLB

PD: Treatment of Motor Symptoms

Dopamine precursor [e.g., Levocarb (Sinemet); Parcopa]

- most effective treatment of *motor symptoms*

Dopamine agonists [e.g., pramipexole (Mirapex); ropinirole (Requip)]:

- effective medication to treat motor symptoms in PD

Both

- improve some aspects of **cognition**
 - attention/concentration, problem solving
- worsen other aspects of **cognition**
 - learning new skills/information
- improve restless leg syndrome (DA better than L-DOPA)
- frequency and dosages increase with disease progression

Dopaminergic Medications: Side Effects

Levocarb < Agonist

- nausea/dizziness
- postural hypotension
- somnolence
- confusion
- hallucinations
- paranoia
- ICDs/punding

Levocarb > Agonist

- dyskinesia

Dopaminergic Medications: Side Effects

Agonist

- sleep attacks
- peripheral edema
- nasal congestion
- can worsen constipation

Other Motor Treatments

Catechol-*O*-Methyltransferase inhibitors [COMT; entacapone(Comtan) or tolcapone(Tasmar)]


- slows the break-down of levodopa, thereby increasing the effect and duration of action of levodopa in the brain
- side effects:
 - increases all dopaminergic side effects
 - diarrhea
 - causes urine and sweat to have an orangey colour

*Note: **Stalevo** is a medication that combines **levocarb/Sinemet+ entacapone/Comtan** in one pill. The medication **tolcapone/Tasmar** is not used because of hepatic side effects.*

Other Motor Treatments

Monoamine oxidase Type B inhibitors [(MAOI-b; selegeline (Deprenyl), rasagiline(Azilect))]

- slows the break-down of levodopa/dopamine, thereby increasing the effect and duration of action of levodopa in the brain
- side effects
 - increases all dopaminergic side effects
 - nausea
 - insomnia
 - theoretical hypertensive crisis if combined with tyramine-rich foods/beverages/dietary supplements
 - not observed in the clinical trials so far



AADC = aromatic amino acid decarboxylase; COMT = catechol-o-methyltransferase ;
 MAOA/B = monoamine oxidase A/B; L-DOPA = L-3, 4-dihydroxyphenylalanine

Other Motor Treatments

Amantadine (Symmetrel)

- antiviral medication causing slight improvement in PD motor symptoms
- decreases dyskinesias
- side effects
 - hallucinations
 - confusion
 - nightmares
 - swelling of the limbs termed *peripheral edema*
 - purplish rash called *livedo reticularis*

Other Motor Treatments

Anticholinergic medications [e.g., trihexyphenidyl (Artane), benztropine (Cogentin)]

- blocks acetylcholine receptors
- minimally reduces tremor
- rarely used, poorly effective
- side effects
 - dry eyes and mouth
 - constipation
 - urinary retention
 - confusion; somnolence
 - hallucinations

Symptoms not Responsive to Dopaminergic Therapy

Motor symptoms

- falls, postural instability
- freezing
- swallowing
- speech

Non-motor symptoms

- all except for cognition, restless leg
- might improve depression but worsen anxiety

Treatment of non-motor symptoms

constipation

- diet, fibre
- docusate (Colace),
- Senna (Senokot),
- lactulose

sexual function

- sildenafil (Viagra)
- yohimbine
- no treatments proven for women

anxiety

- anxiolytic medications [e.g., citalopram (Celexa) venlafaxine (Effexor)]

Depression

- antidepressant medications [e.g., citalopram/(Celexa), venlafaxine/(Effexor)]

Treatment of non-motor symptoms

sleep and wakefulness deficits

- excessive somnolence
 - caffeine
 - modafinil
- vivid dreams/RBD
 - melatonin
 - clonazepam
- insomnia
 - zopiclone

- restless leg syndrome
 - dopamine agonist [e.g., pramipexole (Mirapex)] or precursor [(e.g., levocarb(Sinemet))]

urinary frequency/ urgency

- amitryptiline
- oxybutynin, flavoxate, tolterodrine
- DDAVP

Treatment of non-motor symptoms

sialorrhea

- amitriptyline
- 1 % atropine solution (sublingual)
- oral anticholinergics
- Botox injections

seborrhea

- steroid cream
- ketoconazole cream

DBS: Indications

- typical features of PD
- preferable that the disease duration be at least 5 years (except in cases of disabling tremor or disabling dyskinesias)
- failure of best medical therapy after good initial improvement
- wide fluctuations, difficult to control, but dopamine-responsive (think of DBS as continuous Levocarb infusion)
- absence of significant medical problems
- absence of cognitive impairment
- appropriate age (STN surgery not recommended > 70)

DBS Targets

Thalamus

- tremor

STN & GPi

- ↓ tremor/bradykinesia/rigidity, on-off fluctuations, dystonia
(permit ↓ dopa med reduction ↓ dyskinesia)

STN

- possibly greater improvement in motor scores & med reduction
- smaller size → lower voltage stimulation & improved battery life

GPi DBS:

- possibly better for management of dyskinesias and less psychiatric side effect

Expectations of DBS

- does not cure
- bilateral DBS is often required to improve gait, although sometimes unilateral DBS has a marked effect on walking
- smooths out on-off fluctuations
- improves tremor, stiffness, bradykinesia
- decreased Levocarb dose leads to decreased dyskinesia
- never improves symptoms that are unresponsive to the patient's best "on"
- frequent programming visits, especially initially
- decreases medications in many, but not all, patients.

DBS Complications

Surgery related

- seizure
- hemorrhage
- infection
- permanent deficit (0 to 0.6%)
- misplaced leads

Hardware related

- device malfunction
- lead erosion/disconnection
- lead migration/fracture

Stimulation related

- paresthesias
- muscle contractions
- dysarthria
- diplopia
- cognitive changes
- depression/mania/suicide
- pseudobulbar affect
- obsessions/compulsions
- anxiety/panic attacks
- aggressive behaviour

Overview

- PD is a progressive, multi-system disorder.
- We do a good job of controlling motor symptoms.
- Non-motor symptoms are more difficult to address.
- DBS is an option for some patients only and it only can achieve what best ON state for that patient is with less dyskinesia.

Research

- Patients with early PD no cognitive problems as well as patients with REM Sleep Behaviour disorder no PD no MSA no cognitive impairment.
 - for longitudinal structural, functional MRI, genetic analysis, cognitive, real-world performance (e.g., driving simulation, VR gait studies)